Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
65 hedge funds and large institutions have $92.7M invested in Cidara Therapeutics in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 11 closing their positions.
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
67% more capital invested
Capital invested by funds: $55.6M → $92.7M (+$37.1M)
23% more funds holding
Funds holding: 53 → 65 (+12)
0.28% more ownership
Funds ownership: 2.77% → 3.05% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.78M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.38M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.34M |
| 4 |
AG
Artal Group
Luxembourg
|
+$766K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$709K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.23M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$441K |
| 3 |
WFI
West Family Investments
Carlsbad,
California
|
-$223K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$217K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$151K |
CDTX Hedge Fund Activity: Q2 2020 in Review
65 of the 4,845 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2020, worth a combined $92.7M — up 67% from $55.6M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CDTX positions and 11 closed out — a net gain of 13 holders — while 21 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $4.78M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $3.23M sold.
- 65 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2020, up from 53 in Q1 2020.
- Funds reported $92.7M of Cidara Therapeutics stock for Q2 2020, up 67% quarter-over-quarter.
- 24 funds opened new Cidara Therapeutics positions in Q2 2020 and 11 closed out, a net change of +13 holders.
- The largest Cidara Therapeutics buyer in Q2 2020 was BlackRock, an estimated $4.78M added.
- The largest Cidara Therapeutics seller in Q2 2020 was Stonepine Capital Management, an estimated $3.23M sold.
Based on aggregated 13F filings for Q2 2020.